Legal & General Group’s ADC Therapeutics ADCT Stock Holding History

Legal & General Group’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.64K	Hold	9,012	–	–	﹤0.01%	3320
2026 Q1	$33.8K	Buy	9,012 +88	+1%	+$347	﹤0.01%	2784
2025 Q4	$31.5K	Buy	8,924 +839	+10%	+$3.4K	﹤0.01%	2853
2025 Q3	$32.3K	Hold	8,085	–	–	﹤0.01%	2854
2025 Q2	$21.7K	Sell	8,085 -452	-5%	-$951	﹤0.01%	2974
2025 Q1	$12K	Hold	8,537	–	–	﹤0.01%	3115
2024 Q4	$17K	Hold	8,537	–	–	﹤0.01%	3086
2024 Q3	$26.9K	Buy	8,537 +1,452	+20%	+$4.58K	﹤0.01%	2929
2024 Q2	$22.3K	Buy	+7,085	New	+$28.2K	﹤0.01%	2975
2020 Q3	–	Sell	-2,500	Closed	-$117K	–	3438
2020 Q2	$117K	Buy	+2,500	New	+$94.9K	﹤0.01%	2486

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Legal & General Group's ADCT Position: Q2 2026 in Review

Legal & General Group held its ADC Therapeutics (ADCT) position steady in Q2 2026 at 9,012 shares worth $9.64K. The position accounts for ﹤0.01% of the portfolio, ranked #3320.

Legal & General Group first reported a position in ADCT in Q2 2020 and has held it in 10 quarters since. The position peaked at $117K in Q2 2020. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Legal & General Group held 9,012 shares of ADC Therapeutics worth $9.64K as of Q2 2026.
Legal & General Group left its ADC Therapeutics share count unchanged in Q2 2026.
ADC Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3320 holding.
Legal & General Group first reported a position in ADC Therapeutics in Q2 2020 and has held it in 10 quarters since.
Legal & General Group's ADC Therapeutics position peaked at $117K in Q2 2020.
113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.